Nyxoah SA Discloses Voting Rights and Share Information
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy NYXH?
Source: Newsfilter
- Total Share Capital: As of February 20, 2026, Nyxoah SA's share capital stands at EUR 6,511,048.19, indicating the company's stability and potential for ongoing growth in the capital markets.
- Voting Rights Count: The company currently has 43,662,403 voting rights, all pertaining to ordinary shares, which provides shareholders with substantial participation rights and enhances the transparency of the company's governance structure.
- Unissued Subscription Rights: There are 3,416,319 subscription rights to voting securities that have not yet been issued, indicating potential future capital expansion opportunities and reflecting the company's commitment to shareholder returns.
- Convertible Bonds Information: Nyxoah SA has issued 225 convertible bonds with a nominal value of EUR 91,500 each, which, if fully converted, would increase the voting rights by 4,117,500, showcasing the company's flexibility in financing and confidence in future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NYXH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NYXH
Wall Street analysts forecast NYXH stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.790
Low
5.82
Averages
10.41
High
13.00
Current: 2.790
Low
5.82
Averages
10.41
High
13.00
About NYXH
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nyxoah Secures FDA Approval and Successful U.S. Launch
- FDA Approval and Market Launch: Nyxoah received FDA approval for Genio in August 2025 and successfully launched the product in the U.S. market, marking a significant advancement in the medical device sector that is expected to drive future revenue growth.
- Revenue and Training Success: By Q4 2025, Nyxoah generated $4.5 million in revenue after training 145 surgeons across 125 high-volume stimulation accounts, demonstrating its market penetration capabilities and enhancing its position in a competitive landscape.
- Global Revenue and Operating Loss: The company reported a global gross revenue of EUR 11 million for 2025, while total operating losses increased to EUR 83.5 million due to U.S. commercialization costs, reflecting the financial pressures faced during market expansion.
- Cash Flow and Market Penetration: With a quarterly cash burn rate of approximately EUR 20 million and a cash position of EUR 48 million, Nyxoah faces uncertainties regarding VAC approvals that could impact market penetration speed, necessitating close monitoring of future developments.
See More
Nyxoah (NYXH) Q4 2025 Earnings Call Transcript
See More
Nyxoah SA Discloses Voting Rights and Share Information
- Total Share Capital: As of February 20, 2026, Nyxoah SA's share capital stands at EUR 6,511,048.19, indicating the company's stability and potential for ongoing growth in the capital markets.
- Voting Rights Count: The company currently has 43,662,403 voting rights, all pertaining to ordinary shares, which provides shareholders with substantial participation rights and enhances the transparency of the company's governance structure.
- Unissued Subscription Rights: There are 3,416,319 subscription rights to voting securities that have not yet been issued, indicating potential future capital expansion opportunities and reflecting the company's commitment to shareholder returns.
- Convertible Bonds Information: Nyxoah SA has issued 225 convertible bonds with a nominal value of EUR 91,500 each, which, if fully converted, would increase the voting rights by 4,117,500, showcasing the company's flexibility in financing and confidence in future growth.
See More
Nyxoah (NYXH) Projects 25% Revenue Growth for Q1 2026
- Revenue Expectations: Nyxoah anticipates approximately €6.3 million in gross revenue for Q4 2025, indicating sustained growth potential in the medical device market, particularly in sleep therapy solutions.
- Cash Position: As of December 31, 2025, Nyxoah expects cash, cash equivalents, and financial assets to total around €47.9 million, providing robust financial support for future investments and operations.
- Quarterly Revenue Guidance: The company projects a 25% increase in U.S. net revenue for Q1 2026 compared to Q4 2025, reflecting rising market acceptance and demand for its products, which could positively impact stock performance.
- Financing Plan: Nyxoah announced a multi-part financing plan totaling up to €84 million, which will provide essential funding for research and development as well as market expansion, further solidifying its competitive position in the industry.
See More
Nyxoah Expects 348% Q4 Revenue Growth, $5.7M Forecast
- Revenue Growth Expectations: Nyxoah anticipates Q4 2025 revenue to reach €5.7 million, a 348% increase from €1.3 million in the same quarter last year, indicating strong market demand for its Obstructive Sleep Apnea treatments.
- Significant Annual Performance: The company expects full-year 2025 revenue to hit €10 million, up 122% from €4.5 million in 2024, reflecting successful product promotion and increased customer acceptance in the market.
- Strong Cash Position: As of December 31, 2025, Nyxoah expects to hold approximately €47.9 million in cash and cash equivalents, providing ample funding for future R&D and market expansion initiatives.
- FDA Approval and Market Expansion: Nyxoah's Genio system received FDA approval in August 2025, with 145 surgeons trained and 57 accounts activated in the U.S., marking a successful launch and significant growth potential in the American market.
See More
Nyxoah Receives 3.28% Shareholding Notification from BNP Paribas Asset Management
- Shareholding Notification: On January 8, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management indicating that it holds 1,409,791 voting rights, representing 3.28% of total voting rights, which signifies an increasing importance of this shareholder in the company's structure.
- Threshold Crossing: The notification reveals that BNP Paribas Asset Management crossed the 3% threshold on December 31, 2025, reflecting its confidence in Nyxoah and potentially influencing the company's future strategic decisions.
- Merger Impact: This shareholding change resulted from the merger between BNP Paribas Asset Management Europe SAS and AXA Investment Managers, with the combined entity's holdings crossing a critical ownership threshold, indicating a trend of market consolidation.
- Voting Rights Exercise: BNP Paribas Asset Management Europe SAS, as an investment company, exercises voting rights at its discretion in the absence of specific instructions, which may impact Nyxoah's governance structure and future decision-making processes.
See More
Nyxoah Secures FDA Approval and Successful U.S. Launch
- FDA Approval and Market Launch: Nyxoah received FDA approval for Genio in August 2025 and successfully launched the product in the U.S. market, marking a significant advancement in the medical device sector that is expected to drive future revenue growth.
- Revenue and Training Success: By Q4 2025, Nyxoah generated $4.5 million in revenue after training 145 surgeons across 125 high-volume stimulation accounts, demonstrating its market penetration capabilities and enhancing its position in a competitive landscape.
- Global Revenue and Operating Loss: The company reported a global gross revenue of EUR 11 million for 2025, while total operating losses increased to EUR 83.5 million due to U.S. commercialization costs, reflecting the financial pressures faced during market expansion.
- Cash Flow and Market Penetration: With a quarterly cash burn rate of approximately EUR 20 million and a cash position of EUR 48 million, Nyxoah faces uncertainties regarding VAC approvals that could impact market penetration speed, necessitating close monitoring of future developments.
See More
Nyxoah (NYXH) Q4 2025 Earnings Call Transcript
See More
Nyxoah SA Discloses Voting Rights and Share Information
- Total Share Capital: As of February 20, 2026, Nyxoah SA's share capital stands at EUR 6,511,048.19, indicating the company's stability and potential for ongoing growth in the capital markets.
- Voting Rights Count: The company currently has 43,662,403 voting rights, all pertaining to ordinary shares, which provides shareholders with substantial participation rights and enhances the transparency of the company's governance structure.
- Unissued Subscription Rights: There are 3,416,319 subscription rights to voting securities that have not yet been issued, indicating potential future capital expansion opportunities and reflecting the company's commitment to shareholder returns.
- Convertible Bonds Information: Nyxoah SA has issued 225 convertible bonds with a nominal value of EUR 91,500 each, which, if fully converted, would increase the voting rights by 4,117,500, showcasing the company's flexibility in financing and confidence in future growth.
See More
Nyxoah (NYXH) Projects 25% Revenue Growth for Q1 2026
- Revenue Expectations: Nyxoah anticipates approximately €6.3 million in gross revenue for Q4 2025, indicating sustained growth potential in the medical device market, particularly in sleep therapy solutions.
- Cash Position: As of December 31, 2025, Nyxoah expects cash, cash equivalents, and financial assets to total around €47.9 million, providing robust financial support for future investments and operations.
- Quarterly Revenue Guidance: The company projects a 25% increase in U.S. net revenue for Q1 2026 compared to Q4 2025, reflecting rising market acceptance and demand for its products, which could positively impact stock performance.
- Financing Plan: Nyxoah announced a multi-part financing plan totaling up to €84 million, which will provide essential funding for research and development as well as market expansion, further solidifying its competitive position in the industry.
See More
Nyxoah Expects 348% Q4 Revenue Growth, $5.7M Forecast
- Revenue Growth Expectations: Nyxoah anticipates Q4 2025 revenue to reach €5.7 million, a 348% increase from €1.3 million in the same quarter last year, indicating strong market demand for its Obstructive Sleep Apnea treatments.
- Significant Annual Performance: The company expects full-year 2025 revenue to hit €10 million, up 122% from €4.5 million in 2024, reflecting successful product promotion and increased customer acceptance in the market.
- Strong Cash Position: As of December 31, 2025, Nyxoah expects to hold approximately €47.9 million in cash and cash equivalents, providing ample funding for future R&D and market expansion initiatives.
- FDA Approval and Market Expansion: Nyxoah's Genio system received FDA approval in August 2025, with 145 surgeons trained and 57 accounts activated in the U.S., marking a successful launch and significant growth potential in the American market.
See More
Nyxoah Receives 3.28% Shareholding Notification from BNP Paribas Asset Management
- Shareholding Notification: On January 8, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management indicating that it holds 1,409,791 voting rights, representing 3.28% of total voting rights, which signifies an increasing importance of this shareholder in the company's structure.
- Threshold Crossing: The notification reveals that BNP Paribas Asset Management crossed the 3% threshold on December 31, 2025, reflecting its confidence in Nyxoah and potentially influencing the company's future strategic decisions.
- Merger Impact: This shareholding change resulted from the merger between BNP Paribas Asset Management Europe SAS and AXA Investment Managers, with the combined entity's holdings crossing a critical ownership threshold, indicating a trend of market consolidation.
- Voting Rights Exercise: BNP Paribas Asset Management Europe SAS, as an investment company, exercises voting rights at its discretion in the absence of specific instructions, which may impact Nyxoah's governance structure and future decision-making processes.
See More
